Base de dados : LILACS
Pesquisa : C04.557.337.539.250 [Categoria DeCS]
Referências encontradas : 316 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 32 ir para página                         

  1 / 316 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1049558
Autor: Lobo, Clarisse; .Dantas, Regina Célia; .Oliveira, Sergio; .Marra, Vera; .Monteiro, Luiz Fernando; .Monteiro, Marcos.
Título: Manual do paciente: Leucemia mielóide crônica: orientações básicas aos pacientes e familiares / Patient manual: Chronic myeloid leukemia: basic guidelines for patients and families.
Fonte: Rio de Janeiro; HEMORIO; 2009. 8 p.
Idioma: pt.
Descritores: Leucemia Mielogênica Crônica BCR-ABL Positiva
-Assistência ao Paciente
Limites: Humanos
Tipo de Publ: Guia de Prática Clínica
Responsável: BR454.4


  2 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887072
Autor: Vasconcelos, Erica Rodrigues de Araujo; Bauk, Alexander Richard; Rochael, Mayra Carrijo.
Título: Cutaneous myeloid sarcoma associated with chronic myeloid leukemia
Fonte: An. bras. dermatol;92(5,supl.1):50-52, 2017. graf.
Idioma: en.
Resumo: Abstract: Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites. We report a rare case of cutaneous myeloid sarcoma associated with chronic myeloid leukemia.
Descritores: Neoplasias Cutâneas/patologia
Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia
Sarcoma Mieloide/patologia
Neoplasias Primárias Múltiplas/patologia
-Pele/patologia
Biópsia
Medula Óssea/patologia
Imuno-Histoquímica
Doenças Raras/complicações
Doenças Raras/patologia
Limites: Humanos
Feminino
Adulto
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  3 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837937
Autor: Leitão, Juliana Ribeiro; Valente, Neusa Yuriko Sakai; Kakizaki, Priscila; Veronez, Isis Suga; Pires, Mario Cezar.
Título: Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib
Fonte: An. bras. dermatol;91(5,supl.1):45-47, Sept.-Oct. 2016. graf.
Idioma: en.
Resumo: Abstract Tyrosine kinase inhibitors are effective as a target therapy for malignant neoplasms. Imatinib was the first tyrosine kinase inhibitor used. After its introduction, several other drugs have appeared with a similar mechanism of action, but less prone to causing resistance. Even though these drugs are selective, their toxicity does not exclusively target cancer cells, and skin toxicity is the most common non-hematologic adverse effect. We report an eruption similar to lichen planopilaris that developed during therapy with nilotinib, a second generation tyrosine kinase inhibitor, in a patient with chronic myeloid leukemia resistant to imatinib. In a literature review, we found only one report of non-scarring alopecia due to the use of nilotinib.
Descritores: Pirimidinas/efeitos adversos
Erupção por Droga/etiologia
Erupção por Droga/patologia
Inibidores de Proteínas Quinases/efeitos adversos
Líquen Plano/patologia
-Biópsia
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Alopecia/induzido quimicamente
Alopecia/patologia
Mesilato de Imatinib/efeitos adversos
Antineoplásicos/efeitos adversos
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  4 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-889433
Autor: Nunes, Melise Silveira; Garzon, Litiérri Razia; Rampelotto, Roberta Filipini; Tizotti, Maísa Kräulich; Martini, Rosiéli; Locatelli, Aline; Barbosa, Marcelo; Hörner, Manfredo; Hörner, Rosmari.
Título: Synthesis, characterization and biological activity of a gold(I) triazenide complex against chronic myeloid leukemia cells and biofilm producing microorganisms
Fonte: Braz. J. Pharm. Sci. (Online);53(4):e00191, 2017. tab, graf, ilus.
Idioma: en.
Projeto: CNPq.
Resumo: ABSTRACT The enhancement of anti-leukemia therapy and the treatment of infections caused by multidrug-resistant pathogens are major challenges in healthcare. Although a large arsenal of drugs is available, many of these become ineffective, and as a result, the discovery of new active substances occurs. Notably, triazenes (TZCs) have been consolidated as a promising class of compounds, characterized by significant biological activity, especially antiproliferative and antimicrobial properties. The aim of this study is the synthesis and characterization of a new triazenide complex of gold (I), as well as the in vitro assessment of its antiproliferative activity against the K562 cell line (Chronic Myeloid Leukemia), and antibacterial activity against bacterial isolates of biofilm-producing coagulase-negative staphylococci. The combination of TZC with gold metal tends to have a synergistic effect against all biofilm-producing isolates, with Minimum Inhibitory Concentration values (MIC) between 32 and 64 µg mL-1. It has also shown activity against K562 cell line, getting an IC50=4.96 µM. Imatinib mesylate (Glivec) was used as reference, with IC50=3.86 µM. To the best of our knowledge, this study represents the first report of the activity of a TZC complexed with gold ion in the oxidation state (I) against microorganisms that produce biofilm and K562 cells.
Descritores: Triazenos/síntese química
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Ouro/classificação
-Triazenos/análise
Triazenos/uso terapêutico
Tipo de Publ: Técnicas In Vitro
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  5 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-180276
Autor: Santos, Maria Custódia dos.
Título: Leucemia mielóide crônica / Chronic myeloid leukemia
Fonte: In: Fundaçäo Antonio Prudente. Hospital A. C. Camargo. Manual de condutas diagnósticas e terapêuticas em oncologia. Säo Paulo, Ambito Editores, 1996. p.211-211.
Idioma: pt.
Descritores: Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Limites: Humanos
Masculino
Feminino
Adulto
Responsável: BR1.1 - BIREME
BR1.1/2734.31; BR75.1; 616-006, M319. 3053


  6 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-180271
Autor: Lopes, Luiz Fernando.
Título: Leucemia na infância / Leukemia in childhood
Fonte: In: Fundaçäo Antonio Prudente. Hospital A. C. Camargo. Manual de condutas diagnósticas e terapêuticas em oncologia. Säo Paulo, Ambito Editores, 1996. p.172-172.
Idioma: pt.
Descritores: Leucemia Mieloide
Leucemia-Linfoma Linfoblástico de Células Precursoras
Leucemia Mielogênica Crônica BCR-ABL Positiva
-Leucemia Mieloide/diagnóstico
Leucemia Mieloide/terapia
Leucemia Mieloide/epidemiologia
Fatores de Risco
Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico
Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiologia
Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia
Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico
Leucemia Mielogênica Crônica BCR-ABL Positiva/epidemiologia
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Prognóstico
Limites: Humanos
Recém-Nascido
Lactente
Pré-Escolar
Criança
Adolescente
Responsável: BR1.1 - BIREME
BR1.1/2734.26; BR75.1; 616-006, M319. 3053


  7 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Simöes, Belinda Pinto
Texto completo
Texto completo
Id: lil-582750
Autor: Simões, Belinda Pinto; Braga Junior, José Wilson Ramos; Rego, Maria Aparecida do Carmo; Souza, Cármino Antônio de.
Título: Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Fonte: Rev. bras. hematol. hemoter;33(1):65-72, Feb. 2011. tab.
Idioma: en.
Resumo: Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.
Descritores: Prognóstico
Pirimidinas/uso terapêutico
Resistência a Medicamentos
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Monitoramento de Medicamentos
Receptores Proteína Tirosina Quinases
Resistencia a Medicamentos Antineoplásicos
Monitoramento
Mesilato de Imatinib
Antineoplásicos/administração & dosagem
Limites: Humanos
Tipo de Publ: Revisão
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  8 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-601010
Autor: Martins, Darlize Hübner; Wagner, Sandrine Comparsi; Santos, Tamyris Vianna dos; Lizot, Lilian de Lima Feltraco; Antunes, Marina Venzon; Capra, Marcelo; Linden, Rafael.
Título: Monitoring imatinib plasma concentrations in chronic myeloid leukemia
Fonte: Rev. bras. hematol. hemoter;33(4):302-306, 2011.
Idioma: en.
Resumo: Imatinib has proved to be effective in the treatment of chronic myeloid leukemia, but plasma levels above 1,000 ng/mL must be achieved to optimize activity. Therapeutic drug monitoring of imatinib is useful for patients that do not present clinical response. There are several analytical methods to measure imatinib in biosamples, which are mainly based on liquid chromatography with mass spectrometric or diode array spectrophotometric detection. The former is preferred due to its lower cost and wider availability. The present manuscript presents a review of the clinical and analytical aspects of the therapeutic drug monitoring of imatinib in the treatment of chronic myeloid leukemia. The review includes references published over the last 10 years. There is evidence that the monitoring of plasmatic levels of imatinib is an useful alternative, especially considering the wide pharmacokinetic variability of this drug.
Descritores: Plasma
Pirimidinas/farmacocinética
Algoritmos
Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
Cromatografia
Monitoramento de Medicamentos
Tratamento Farmacológico
Citocromo P-450 CYP3A/metabolismo
Mesilato de Imatinib
/farmacocinética
FRUCTANSTEMEFOS/farmacocinética
Antineoplásicos/uso terapêutico
Tipo de Publ: Revisão
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  9 / 316 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-648527
Autor: Carvalho, Daiana Landenberger de; Barbosa, Cristian Dias; Carvalho, André Luiz de; Beck, Sandra Trevisan.
Título: Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
Fonte: Rev. bras. hematol. hemoter;34(4):280-284, 2012. tab.
Idioma: en.
Resumo: OBJECTIVE: This study aimed to verify the association between human leukocyte antigens and the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia patients. METHODS: Forty-seven bcr-abl positive individuals were evaluated. Typing was performed bymicrolymphocytotoxicity and molecular biological methods (human leukocyte antigens Class I and Class II). A control group was obtained from the data of potential bone marrow donors registered in the Brazilian Bone Marrow Donor Registry (REDOME). RESULTS: Positive associations with HLA-A25 and HLA-B18 were found for the b2a2 transcript, as well as a tendency towards a positive association with HLA-B40 and a negative association with HLA-A68. The b3a2 transcript showed positive associations with HLA-B40 and HLA-DRB1*3. CONCLUSION: The negative association between human leukocyte antigens and the BCR-ABL transcript suggests that binding and presentation of peptides derived from the chimeric protein are effective to increase a cytotoxic T lymphocyte response appropriate for the destruction of leukemic cells.
Descritores: Cromossomo Filadélfia
Leucemia Mielogênica Crônica BCR-ABL Positiva
Leucemia
Leucemia Mieloide
Predisposição Genética para Doença
Leucemia-Linfoma Linfoblástico de Células Precursoras
Antígenos HLA
Limites: Humanos
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  10 / 316 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-654979
Autor: Souza, Carmino Antonio de; Pagnano, Katia Borgia Barbosa; Bendit, Israel; Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Coelho, Arthur Moellmann; Funke, Vaneuza Araújo Moreira; Bernardo, Wanderley Marques.
Título: Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012
Fonte: Rev. bras. hematol. hemoter;34(5):367-382, 2012. tab.
Idioma: en.
Descritores: Leucemia Mielogênica Crônica BCR-ABL Positiva/diagnóstico
Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM



página 1 de 32 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde